株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

コンパニオン診断の世界市場 ~2024年:ポリメラーゼ連鎖反応 (PCR)・次世代シーケンシング (NGS) ・in situハイブリダイゼーション (ISH) ・免疫組織化学 (IHC)

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User, Region - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 538593
出版日 ページ情報 英文 240 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.69円で換算しております。
Back to Top
コンパニオン診断の世界市場 ~2024年:ポリメラーゼ連鎖反応 (PCR)・次世代シーケンシング (NGS) ・in situハイブリダイゼーション (ISH) ・免疫組織化学 (IHC) Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User, Region - Global Forecast to 2024
出版日: 2019年09月16日 ページ情報: 英文 240 Pages
概要

世界のコンパニオン診断市場は、2019年の35億米ドルから2024年の73億米ドルへ達すると予測され、この間は15.7%のCAGR (年間複合成長率) が見込まれています。コンパニオン診断市場の成長は、標的療法に対するニーズの高まり、個別化医療の重要性の拡大といった様々な要因と結びついています。世界的な癌発症率の上昇、コンパニオン診断の応用領域の拡大、および次世代シーケンシングの需要の増大なども、コンパニオン診断市場で活動する企業へ成長機会を示しています。しかし、コンパニオン診断検査の高コスト性、各地域における不確かな医療費償還シナリオなどは、予測期間中の市場成長へある程度影響を及ぼしています。

当レポートでは、世界のコンパニオン診断の市場を調査し、市場の定義と概要、市場成長への各種影響因子および市場機会の分析、製品&サービス・技術・適応症・エンドユーザー・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

538593_3_FIGURE 11_GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 市場概要
  • アジア太平洋のコンパニオン診断市場:エンドユーザー別
  • 地域ミックス:コンパニオン診断市場
  • コンパニオン診断市場:新興諸国 vs. 先進諸国
  • コンパニオン診断市場の地域スナップショット

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 産業考察

  • イントロダクション
  • 産業動向
  • 規制分析
  • 製品パイプライン分析

第7章 コンパニオン診断市場:製品・サービス別

  • イントロダクション
  • アッセイ・キット・試薬
  • ソフトウェア・サービス

第8章 コンパニオン診断市場:技術別

  • イントロダクション
  • ポリメラーゼ連鎖反応 (PCR)
  • 次世代シーケンシング (NGS)
  • in situハイブリダイゼーション (ISH)
  • 免疫組織化学 (IHC)
  • その他の技術

第9章 コンパニオン診断市場:適応症別

  • イントロダクション
    • 乳癌
    • 肺癌
    • 大腸癌
    • 黒色腫 (メラノーマ)
    • 胃癌
  • 神経疾患
  • 感染症
  • 心血管疾患
  • その他

第10章 コンパニオン診断市場:エンドユーザー別

  • イントロダクション
  • 医薬品・バイオ医薬品企業
  • リファレンスラボラトリー
  • CRO
  • その他

第11章 コンパニオン診断市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • スイス
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
  • ラテンアメリカ
  • 中東・アフリカ

第12章 競合環境

  • 概要
  • 市場シェア分析
  • 競合状況・動向、ほか

第13章 企業プロファイル

  • F. HOFFMANN-LA ROCHE AG
  • AGILENT TECHNOLOGIES, INC.
  • QIAGEN N.V.
  • ABBOTT LABORATORIES, INC.
  • ALMAC GROUP
  • DANAHER CORPORATION
  • ILLUMINA, INC.
  • BIOMERIEUX SA
  • MYRIAD GENETICS, INC.
  • SYSMEX CORPORATION
  • THERMO FISHER SCIENTIFIC INC.
  • ABNOVA CORPORATION
  • GUARDANT HEALTH, INC.

第14章 付録

図表

LIST OF TABLES

  • TABLE 1: STANDARD CURRENCY CONVERSION RATES
  • TABLE 2: COMPANION DIAGNOSTICS MARKET SNAPSHOT, 2019 VS. 2024
  • TABLE 3: COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
  • TABLE 4: PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
  • TABLE 5: LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
  • TABLE 6: RECENT COLLABORATIONS IN THE COMPANION DIAGNOSTICS MARKET
  • TABLE 7: US: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 8: JAPAN: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 9: CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 10: INDIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 11: COMPANION DIAGNOSTICS PRODUCT PIPELINE ANALYSIS, BY MARKET PLAYER: CURRENT MARKET SCENARIO
  • TABLE 12: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 13: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, & REAGENTS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 14: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 15: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 16: COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR THE DETECTION OF RAS/BRAF MUTATION
  • TABLE 17: MAJOR PCR TESTS/KITS AVAILABLE IN THE MARKET
  • TABLE 18: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 19: MAJOR NGS TESTS/KITS AVAILABLE IN THE MARKET
  • TABLE 20: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 21: MAJOR ISH TESTS/KITS AVAILABLE IN THE MARKET
  • TABLE 22: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 23: MAJOR IHC TESTS/KITS AVAILABLE IN THE MARKET
  • TABLE 24: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 25: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 26: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 27: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 28: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 29: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 30: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 31: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 32: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 33: COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 34: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 35: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 36: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 37: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 38: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 39: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 40: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 41: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 42: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 43: COMPANION DIAGNOSTICS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 44: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 45: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 46: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 47: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 48: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 49: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 50: US: KEY MACROINDICATORS
  • TABLE 51: US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 52: US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 53: US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 54: US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 55: US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 56: CANADA: KEY MACROINDICATORS
  • TABLE 57: CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 58: CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 59: CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 60: CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 61: CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 62: EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 63: EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 64: EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 65: EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 66: EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 67: EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 68: GERMANY: KEY MACROINDICATORS
  • TABLE 69: GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 70: GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 71: GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 72: GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 73: GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 74: UK: KEY MACROINDICATORS
  • TABLE 75: UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 76: UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 77: UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 78: UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 79: UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 80: SWITZERLAND: KEY MACROINDICATORS
  • TABLE 81: SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 82: SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 83: SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 84: SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 85: SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 86: FRANCE: KEY MACROINDICATORS
  • TABLE 87: FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 88: FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 89: FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 90: FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 91: FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 92: ITALY: KEY MACROINDICATORS
  • TABLE 93: ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 94: ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 95: ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 96: ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 97: ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 98: SPAIN: KEY MACROINDICATORS
  • TABLE 99: SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 100: SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 101: SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 102: SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 103: SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 104: ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 105: ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 106: ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 107: ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 108: ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 109: APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 110: APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 111: APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 112: APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 113: APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 114: APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 115: JAPAN: KEY MACROINDICATORS
  • TABLE 116: JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 117: JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 118: JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 119: JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 120: JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 121: CHINA: KEY MACROINDICATORS
  • TABLE 122: CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 123: CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 124: CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 125: CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 126: CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 127: INDIA: KEY MACROINDICATORS
  • TABLE 128: INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 129: INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 130: INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 131: INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 132: INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 133: AUSTRALIA: KEY MACROINDICATORS
  • TABLE 134: AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 135: AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 136: AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 137: AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 138: AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 139: ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 140: ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 141: ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 142: ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 143: ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 144: LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 145: LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 146: LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 147: LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 148: LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 149: LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 150: BRAZIL: KEY MACROINDICATORS
  • TABLE 151: BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 152: BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 153: BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 154: BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 155: BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 156: MEXICO: KEY MACROINDICATORS
  • TABLE 157: MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 158: MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 159: MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 160: MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 161: MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 162: ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 163: ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 164: ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 165: ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 166: ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 167: MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2024 (USD MILLION)
  • TABLE 168: MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 169: MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 170: MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 171: MEA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 172: GROWTH STRATEGY MATRIX (2016-2019)
  • TABLE 173: PRODUCT LAUNCHES & APPROVALS, 2016-2019
  • TABLE 174: PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS, 2016-2019
  • TABLE 175: ACQUISITIONS, 2016-2019
  • TABLE 176: EXPANSIONS, 2016-2019

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: PRIMARY SOURCES
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: MARKET SIZE APPROACH
  • FIGURE 5: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS. 2024 (USD MILLION)
  • FIGURE 9: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2019 VS. 2024 (USD MILLION)
  • FIGURE 10: COMPANION DIAGNOSTICS MARKET, BY END USER, 2019 VS. 2024 (USD MILLION)
  • FIGURE 11: GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET
  • FIGURE 12: INCREASING DEMAND FOR TARGETED THERAPIES AND PERSONALIZED MEDICINE IN THE PHARMACEUTICAL INDUSTRY IS DRIVING MARKET GROWTH
  • FIGURE 13: PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES COMMANDED THE LARGEST SHARE OF THE APAC COMPANION DIAGNOSTICS MARKET IN 2018
  • FIGURE 14: ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 15: DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
  • FIGURE 16: CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 17: COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18: GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2016
  • FIGURE 19: GLOBAL CANCER INCIDENCE, 2008-2030
  • FIGURE 20: PREMARKET NOTIFICATION: 510(K) APPROVAL FOR COMPANION DIAGNOSTIC PRODUCTS
  • FIGURE 21: INDIA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 22: ASSAYS, KITS, & REAGENTS TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 23: POLYMERASE CHAIN REACTION TO DOMINATE THE COMPANION DIAGNOSTICS TECHNOLOGY MARKET DURING THE FORECAST PERIOD
  • FIGURE 24: CANCER INDICATION SEGMENT TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 25: BREAST CANCER TO DOMINATE THE COMPANION DIAGNOSTICS MARKET FOR CANCER DURING THE FORECAST PERIOD
  • FIGURE 26: GLOBAL LUNG CANCER INCIDENCE, 2012-2030
  • FIGURE 27: PHARMACEUTICAL& BIOPHARMACEUTICAL COMPANIES TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
  • FIGURE 28: GEOGRAPHIC SNAPSHOT: CHINA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 29: NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 30: EUROPE: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 31: ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 32: KEY DEVELOPMENTS IN THE COMPANION DIAGNOSTICS MARKET BETWEEN JANUARY 2016 AND MAY 2019
  • FIGURE 33: COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
  • FIGURE 34: COMPANION DIAGNOSTICS MARKET COMPETITIVE LEADERSHIP MAPPING, 2018
  • FIGURE 35: PRODUCT LAUNCHES & APPROVALS WAS THE KEY GROWTH STRATEGY ADOPTED BY MAJOR PLAYERS BETWEEN 2016 & 2019
  • FIGURE 36: F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • FIGURE 37: AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 38: QIAGEN N.V.: COMPANY SNAPSHOT
  • FIGURE 39: ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 40: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 41: ILLUMINA INC.: COMPANY SNAPSHOT
  • FIGURE 42: BIOMERIEUX SA: COMPANY SNAPSHOT
  • FIGURE 43: MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
  • FIGURE 44: SYSMEX CORPORATION: COMPANY SNAPSHOT
  • FIGURE 45: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • FIGURE 46: GUARDANT HEALTH, INC.: COMPANY SNAPSHOT
目次
Product Code: MD 5463

"The companion diagnostics market is estimated to grow at a CAGR of 15.7%"

The companion diagnostics market is projected to reach 7.3 billion by 2024 from USD 3.5 billion in 2019, at a CAGR of 15.7%. The growth of the companion diagnostics industry is tied primarily to its various advantages, the growing need for targeted therapy, the increasing importance of personalized medicine. Moreover, the increasing global incidence of cancer, ever-increasing application areas of companion diagnostics, rising demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the increasing number of clinical trials are expected to present growth opportunities for players in the market. However, the high cost of companion diagnostic tests and the uncertain reimbursement scenario in different regions affect market growth to a certain extent during the forecast period.

"Cancer segment to witness the highest growth during the forecast period"

The cancer segment is estimated to grow at the highest CAGR during the forecast period. This can be attributed primarily to the increasing global incidence of cancer, the growing role of companion diagnostics in personalized medicine treatment for cancer, the rising utility of biomarkers in the diagnosis of cancer, technological advancements in cancer diagnostics at the molecular level, and the availability of funding for cancer research.

"Pharmaceutical & biopharmaceutical companies segment to grow at the highest CAGR in the companion diagnostics market, by end-user"

The major factors driving the demand for pharmaceutical & biopharmaceutical companies in companion diagnostics are growing prominence in drug development and the growing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

"APAC market to witness the highest growth during the forecast period"

Asia Pacific is estimated to be the fastest-growing regional market for companion diagnostics during the forecast period. The high incidence of cancer, growing proteomics & genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are some of the major factors driving the growth of this market.

A breakdown of the primary participants in this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3-20%
  • By Designation: C-level-35%, Director Level-25%, and Others-40%
  • By Region: North America-45%, Europe-20%, Asia Pacific-30%, Rest of the World (RoW)-5%

The prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMerieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), and Guardant Health, Inc. (US).

Research Coverage:

This report analyzes the market for various companion diagnostics and their adoption patterns. It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its segments (by product & service, technology, indication, end-user, and region). The report also includes an in-depth competitive analysis of key market players along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or any combination of the below mentioned five strategies for strengthening their market presence.

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion diagnostics market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service launches in the global companion diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion diagnostics market
  • Competitive Assessment: In-depth assessment of product offered, market shares, growth strategies, and revenue analysis of leading players in the global companion diagnostics market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 COMPANION DIAGNOSTICS: MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER (2018)
  • 4.3 REGIONAL MIX: COMPANION DIAGNOSTICS MARKET
  • 4.4 COMPANION DIAGNOSTICS MARKET: DEVELOPING VS. DEVELOPED COUNTRIES
  • 4.5 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Advantages of companion diagnostics
      • 5.2.1.2 Growing need for targeted therapy
      • 5.2.1.3 Growing importance of personalized medicine
      • 5.2.1.4 Increasing global incidence of cancer
      • 5.2.1.5 Growing application areas of companion diagnostics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of companion diagnostic tests
      • 5.2.2.2 Uncertain reimbursement scenario in different regions
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for next-generation sequencing
      • 5.2.3.2 Growing significance of companion diagnostics in drug development
      • 5.2.3.3 Increasing number of clinical trials
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of trained professionals

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 INDUSTRY TRENDS
    • 6.2.1 GROWING FOCUS ON LIQUID BIOPSY IN COMPANION DIAGNOSTICS
    • 6.2.2 INCREASING COLLABORATIONS
  • 6.3 REGULATORY ANALYSIS
    • 6.3.1 NORTH AMERICA
      • 6.3.1.1 US
      • 6.3.1.2 Canada
    • 6.3.2 EUROPE
    • 6.3.3 ASIA PACIFIC
      • 6.3.3.1 Australia
      • 6.3.3.2 Japan
      • 6.3.3.3 China
      • 6.3.3.4 India
    • 6.3.4 BRAZIL
  • 6.4 PRODUCT PIPELINE ANALYSIS

7 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 7.1 INTRODUCTION
  • 7.2 ASSAYS, KITS, & REAGENTS
    • 7.2.1 THE VOLUME OF CDX TESTS PERFORMED IN LABORATORIES IS INCREASING, WHICH SUPPORTS THE ADOPTION OF ASSAYS & KITS
  • 7.3 SOFTWARE & SERVICES
    • 7.3.1 THE NEED FOR EFFECTIVE DATA MANAGEMENT SOFTWARE WITHIN LABORATORIES IS INCREASING, CONTRIBUTING TO THE GROWTH OF THE COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET

8 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 POLYMERASE CHAIN REACTION (PCR)
    • 8.2.1 GROWING APPLICATIONS OF PCR TECHNOLOGIES IN THE FIELD OF PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS DRIVE THE GROWTH OF THIS SEGMENT
  • 8.3 NEXT-GENERATION SEQUENCING (NGS)
    • 8.3.1 THE NGS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • 8.4 IN SITU HYBRIDIZATION (ISH)
    • 8.4.1 INCREASING ADOPTION OF ISH IS MAINLY DUE TO ADVANCEMENTS IN HYBRIDIZATION AND ITS DEMAND IN SMALL-TUMOR DIAGNOSTICS
  • 8.5 IMMUNOHISTOCHEMISTRY (IHC)
    • 8.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES IN COMPANION DIAGNOSTICS TO DRIVE THE GROWTH OF THIS SEGMENT
  • 8.6 OTHER TECHNOLOGIES

9 COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 9.1 INTRODUCTION
  • 9.2 CANCER
    • 9.2.1 BREAST CANCER
      • 9.2.1.1 Breast cancer is the most common cancer among women-a key factor contributing to the large share of this market segment
    • 9.2.2 LUNG CANCER
      • 9.2.2.1 Growing demand for therapeutic drugs and their high efficacy in the treatment of lung cancer increase the adoption of companion diagnostics in this segment
    • 9.2.3 COLORECTAL CANCER
      • 9.2.3.1 Growing need for molecular profiling of primary tumors in colorectal cancer to drive growth in this market segment
    • 9.2.4 MELANOMA
      • 9.2.4.1 Growing incidence of melanoma, along with the need for the early diagnosis of genetic-mutated tumors, drives the demand for companion diagnostics
    • 9.2.5 GASTRIC CANCER
      • 9.2.5.1 Increasing focus of market players on the development of tests and kits for gastric cancer indications to drive market growth
  • 9.3 NEUROLOGICAL DISEASES
    • 9.3.1 GROWING NUMBER OF DIAGNOSTIC TECHNOLOGIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES TO BOOST THE ADOPTION OF COMPANION DIAGNOSTICS IN THIS SEGMENT
  • 9.4 INFECTIOUS DISEASES
    • 9.4.1 GROWING FOCUS OF COMPANION DIAGNOSTIC PLAYERS ON ORPHAN INDICATIONS TO PROPEL THE GROWTH OF THIS SEGMENT DURING THE FORECAST PERIOD
  • 9.5 CARDIOVASCULAR DISEASES
    • 9.5.1 GROWING DEMAND FOR TARGETED THERAPIES DUE TO HIGH INCIDENCE AND MORTALITY RATE OF CARDIOVASCULAR DISEASES TO DRIVE GROWTH IN THIS SEGMENT
  • 9.6 OTHER INDICATIONS

10 COMPANION DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 10.2.1 WIDE USAGE OF COMPANION DIAGNOSTICS IN PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES OWING TO THEIR GROWING PROMINENCE IN DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
  • 10.3 REFERENCE LABORATORIES
    • 10.3.1 GROWING INCIDENCE OF DISEASES SUCH AS CANCER AND THE RISING DEMAND FOR TARGETED THERAPIES TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
  • 10.4 CONTRACT RESEARCH ORGANIZATIONS
    • 10.4.1 CROS OFFER A COMPLETE RANGE OF COMPANION DIAGNOSTIC SERVICES RANGING FROM COMPANION DIAGNOSTIC DEVELOPMENT TO TARGETED THERAPY-RELATED CLINICAL TRIALS
  • 10.5 OTHER END USERS

11 COMPANION DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 US
      • 11.2.1.1 The US is the largest market for companion diagnostics in North America
    • 11.2.2 CANADA
      • 11.2.2.1 Government initiatives to promote companion diagnostics in various indications are expected to drive market growth in Canada
  • 11.3 EUROPE
    • 11.3.1 GERMANY
      • 11.3.1.1 Germany is a major market for pharmaceutical and biotechnology products in Europe
    • 11.3.2 UK
      • 11.3.2.1 Growth in the country's life science industry and increasing research are key factors driving market growth in the UK
    • 11.3.3 SWITZERLAND
      • 11.3.3.1 Switzerland boasts a strong research-oriented pharma industry, a key factor supporting market growth
    • 11.3.4 FRANCE
      • 11.3.4.1 Increasing government funding for genomics and personalized therapeutics R&D is driving market growth
    • 11.3.5 ITALY
      • 11.3.5.1 Growing disease prevalence has contributed to the demand for better, more powerful therapeutics in Italy
    • 11.3.6 SPAIN
      • 11.3.6.1 Medical institutes in Spain are increasingly focusing on cancer biomarker research
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 JAPAN
      • 11.4.1.1 Japan holds the largest share of the market in APAC
    • 11.4.2 CHINA
      • 11.4.2.1 China is one of the most prominent research markets, worldwide
    • 11.4.3 INDIA
      • 11.4.3.1 Initiatives by the Indian government to tackle the growing burden of cancer are expected to increase the adoption of companion diagnostics in the country
    • 11.4.4 AUSTRALIA
      • 11.4.4.1 Growing geriatric population in Australia has resulted in initiatives to enhance healthcare access and infrastructure
    • 11.4.5 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 BRAZIL
      • 11.5.1.1 Brazil dominates the Latin American companion diagnostics market
    • 11.5.2 MEXICO
      • 11.5.2.1 Mexico is emerging as a prominent medical tourism hub
    • 11.5.3 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 RISING CANCER INCIDENCE RATE HAS ATTRACTED STAKEHOLDER ATTENTION TO REGIONAL MARKETS IN MEA

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 MARKET SHARE ANALYSIS
  • 12.3 COMPETITIVE LEADERSHIP MAPPING, 2018
  • 12.4 VENDOR INCLUSION CRITERIA
  • 12.5 VENDOR DIVE
    • 12.5.1 VISIONARY LEADERS
    • 12.5.2 INNOVATORS
    • 12.5.3 EMERGING COMPANIES
    • 12.5.4 DYNAMIC DIFFERENTIATORS
  • 12.6 COMPETITIVE SITUATIONS AND TRENDS
    • 12.6.1 PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS
    • 12.6.2 ACQUISITIONS

13 COMPANY PROFILES

(Business overview, Products and Services offered, Recent developments, MNM view)*

  • 13.1 F. HOFFMANN-LA ROCHE AG
  • 13.2 AGILENT TECHNOLOGIES, INC.
  • 13.3 QIAGEN N.V.
  • 13.4 ABBOTT LABORATORIES, INC.
  • 13.5 ALMAC GROUP
  • 13.6 DANAHER CORPORATION
  • 13.7 ILLUMINA INC.
  • 13.8 BIOMERIEUX SA
  • 13.9 MYRIAD GENETICS, INC.
  • 13.10 SYSMEX CORPORATION
  • 13.11 THERMO FISHER SCIENTIFIC, INC.
  • 13.12 ABNOVA CORPORATION
  • 13.13 GUARDANT HEALTH, INC.

Business overview, Products and Services offered, Recent developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 14.2 DISCUSSION GUIDE
  • 14.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4 AVAILABLE CUSTOMIZATIONS
  • 14.5 RELATED REPORTS
  • 14.6 AUTHOR DETAILS
Back to Top